Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 341

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Open access
Yu, Helena A., Sima, Camelia S., Huang, James, Solomon, Stephen B., Rimner, Andreas, Paik, Paul, Pietanza, M. Catherine, Azzoli, Christopher G., Rizvi, Naiyer A., Krug, Lee M., Miller, Vincent A., Kris, Mark G., Riely, Gregory J.·2013·Journal of Thoracic Oncology

Abstract

Background: Development of acquired resistance limits the utility of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung cancers. There are no accepted targeted therapies for use after acquired resistance develops. Metastasectomy is used in other cancers to manage oligometastatic disease. We hypothesized that local therapy is associated with improved outcomes in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI. Methods: Patients who received non–central nervous system local therapy were identified by a review of data from a prospective biopsy protocol for patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI therapy and other institutional biospecimen registry protocols. Results: Eighteen patients were identified, who received elective local therapy (surgical resection, radiofrequency ablation, or radiation). Local therapy was well tolerated, with 85% of patients restarting TKI therapy within 1 month of local therapy. The median time to progression after local therapy was 10 months (95% confidence interval [CI]: 2–27 months). The median time until a subsequent change in systemic therapy was 22 months (95% CI: 6–30 months). The median overall survival from local therapy was 41 months (95% CI: 26–not reached). Conclusions: EGFR-mutant lung cancers with acquired resistance to EGFR TKI therapy are amenable to local therapy to treat oligometastatic disease when used in conjunction with continued EGFR inhibition. Local therapy followed by continued treatment with an EGFR TKI is well tolerated and associated with long PFS and OS. Further study in selected individuals in the context of other systemic options is required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e31827e1f83

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 341

Metadata

Authors
Yu, H. A., Sima, C. S., Huang, J., Solomon, S. B., Rimner, A., Paik, P., Pietanza, M. C., Azzoli, C. G., Rizvi, N. A., Krug, L. M., Miller, V. A., Kris, M. G., & Riely, G. J.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2013-03
Volume
8
Issue
3
Pages
346-351
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2027242209
Cited by
341
References
13
FWCI
26.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. https://app.cochat.ai/papers/10.1097/jto.0b013e31827e1f83
The paper
Yu, H. A., Sima, C. S., Huang, J., Solomon, S. B., Rimner, A., Paik, P., Pietanza, M. C., Azzoli, C. G., Rizvi, N. A., Krug, L. M., Miller, V. A., Kris, M. G., & Riely, G. J. (2013). Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0b013e31827e1f83

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.